



COALITION AGAINST SOCIALIZED MEDICINE

a Project of THE CONSERVATIVE POLITICAL ACTION COALITION

Upcoming Comment Periods

- **USTR: Section 301 – Germany’s Persistent Underpayment for Innovative Pharmaceutical Products**
 - **Summary:** The USTR seeks public comment on whether Germany’s government-imposed pricing policies unfairly undervalue innovative American medicines, shift R&D costs onto U.S. patients and taxpayers, and warrant action under Section 301 of the Trade Act.
 - **Deadline:** August 10, 2026
 - **Submission Link:** <https://comments.ustr.gov/s/docket?docketNumber=USTR-2026-0463>
- **Senate Finance Committee Democrats Request for Information: Commonsense Policy Options to Lower Drug Prices for Patients**
 - **Summary:** Senate Finance Committee Democrats seek stakeholder feedback on policy proposals to lower prescription drug prices, reduce patients’ out-of-pocket costs, and promote biopharmaceutical innovation as they develop future drug pricing legislation.
 - **Deadline:** August 17, 2026
 - **Submission Link:** Submit written comments to drugs@finance.senate.gov
- **CMS: Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program**
 - **Summary:** CMS seeks public comment on proposed policies implementing the Inflation Reduction Act’s Medicare Drug Price Negotiation Program, including changes related to the IPAY 2029 negotiation cycle and the Medicare Part D prescription drug benefit.
 - **Deadline:** August 17, 2026
 - **Submission Link:** <https://www.federalregister.gov/documents/2026/06/16/2026-12059/medicare-drug-price-negotiation-program-and-medicare-prescription-drug-benefit-program>
- **Chairman Cassidy Unveils Landmark Discussion Draft to Fix 340B, Lower Health Costs for American Patients & Families**
 - **Summary:** Senator Bill Cassidy (R-LA) seeks stakeholder feedback on legislative reforms to strengthen oversight of the 340B Drug Pricing Program by increasing transparency, tightening program integrity requirements, and ensuring 340B discounts are used to benefit eligible patients as Congress intended.
 - **Deadline:** August 28, 2026
 - **Submission Link:** Submit written comments to 340bforpatients@help.senate.gov